ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,969.34
0.35%
Dow Jones
44,296.51
0.97%
US Dollar vs MXN
20.4285
0.00%
Brent Oil
74.65
0.00%
Bitcoin
98,276.75
0.50%
Pepperstone
Advertisement
Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ

  6. Anavex Life Sciences Corporation (AVXL) Cotización

Anavex Life Sciences Corporation

Anavex Life Sciences Corporation (AVXL)

NASDAQ
9.11
0.09
(1.00%)
Cerrado 24 Noviembre 3:00PM
Delayed by 15 minutes
8.97
-0.14
(-1.54%)
Fuera de horario: 6:59PM
Delayed by 15 minutes

Su centro para precios en tiempo real, ideas y debates en vivo

Premium

Estadísticas y detalles clave

Último Precio
8.97
Postura de Compra
8.77
Postura de Venta
9.60
Volume Operado de la Acción
1,942,913
8.60 Rango del Día 9.20
3.25 Rango de 52 semanas 10.45
Capitalización de Mercado [m]
760.616M
Precio Anterior
9.02
Precio de Apertura
8.91
Hora
176
@
8.97
(formt)
Última hora de negociación
Volumen financiero
US$ 17,341,286
Precio Promedio Ponderado
8.9254
Volumen promedio (3 m)
1,007,412
Acciones en circulación
84,795,517
Rendimiento del Dividendo
-
Ratio Precio/Utilidad
-16.21
Beneficio por acción (BPA)
-0.56
turnover
-
Beneficio neto
-47.51M

Acerca de Anavex Life Sciences Corporation

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are u... Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are used to select patients that will receive the therapeutic benefit for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound ANAVEX 2-73 is being developed to treat Alzheimer's disease, Parkinson's disease, and potentially other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder caused by mutations in the X-linked gene, methyl-CpG-binding protein 2. Mostrar más

Sector
Biological Pds,ex Diagnstics
Industria
Biological Pds,ex Diagnstics
Sitio web
www.anavex.com
Sede
Carson City, Nevada, USA
Fundado
-
Anavex Life Sciences Corporation is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker AVXL. The last closing price for Anavex Life Sciences was US$9.02. Over the last year, Anavex Life Sciences shares have traded in a share price range of US$ 3.25 to US$ 10.45.

Anavex Life Sciences currently has 84,795,517 shares in issue. The market capitalisation of Anavex Life Sciences is US$764.86 million. Anavex Life Sciences has a price to earnings ratio (PE ratio) of -16.21.

Flujo de Opciones Anavex Life Sciences (AVXL)

Ver flujo de opciones completo

Flujo General

Optimista

Prima Neta

27k

Calls / Puts

100.00%

Comp. / Vent.

0.00%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

AVXL Últimas noticias

Más noticias

Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024

Data of Blarcamesine confirm upstream SIGMAR1 activation Presented as Late Breaking Oral Communications at Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2024 Oral, once daily...

31 Octubre 2024
GlobeNewswire Inc.

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition

ZenaTech, Inc. (NASDAQ: ZENA) Software Company Acquisition     Miami, FL – October 23, 2024 -- InvestorsHub NewsWire – EmergingGrowth.com, a leading...

23 Octubre 2024
InvestorsHub NewsWire

Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia

Part A of the placebo-controlled Phase 2 study has been completed ANAVEX®3-71 demonstrates a dose-dependent pharmacodynamic effect on objective EEG biomarkers of schizophrenia Patients are...

17 Octubre 2024
GlobeNewswire Inc.

ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management

ZenaTech, Inc. (NASDAQ: ZENA) First US Trial of IQ Nano Drone for Inventory Management  Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through...

15 Octubre 2024
InvestorsHub NewsWire

ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today

ZenaTech, Inc. (NASDAQ: ZENA) To Commence Trading Today   Commercial Drone market expected to grow at 23.7 CAGR (Compound Annual Growth Rate) through 2030     Miam...

01 Octubre 2024
InvestorsHub NewsWire

Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024

NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

03 Septiembre 2024
GlobeNewswire Inc.

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

06 Agosto 2024
Edgar (US Regulatory)

Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update

Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...

06 Agosto 2024
GlobeNewswire Inc.

Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024

NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated...

01 Agosto 2024
GlobeNewswire Inc.

Form 8-K - Current report

30 Julio 2024
Edgar (US Regulatory)
Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
10.9712.12589.397.1814760828.05865467CS
43.5966.72862453535.3810.455.2217042857.74223876CS
122.9749.5610.454.930110074126.76993631CS
264.64107.1593533494.3310.453.5110530155.90271429CS
522.2132.69230769236.7610.453.2512005045.85736057CS
156-11.387-55.93653288820.35721.33.2511588928.74996646CS
2606.57273.752.431.52.2131744410.43692118CS

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
PDYNPalladyne AI Corporation
US$ 4.59
(129.50%)
83M
QMCOQuantum Corporation
US$ 9.11
(126.62%)
39.41M
NANano Labs Ltd
US$ 8.26
(89.02%)
2.03M
XCURExicure Inc
US$ 18.60
(71.27%)
4.36M
SKKSKK Holdings Limited
US$ 1.75
(59.09%)
95.06M
AMIXAutonomix Medical Inc
US$ 6.21
(-54.07%)
897.51k
CETXCemtrex Inc
US$ 0.1146
(-41.74%)
22.89M
MSWMing Shing Group Holdings Ltd
 5.90
(-35.52%)
417.08k
RMSGReal Messenger Corporation
US$ 3.09
(-26.25%)
305.85k
ENSCEnsysce Biosciences Inc
US$ 0.4414
(-25.49%)
3.93M
ELABElevai Labs Inc
US$ 0.0201
(-0.50%)
425.38M
NVDANVIDIA Corporation
US$ 141.95
(-3.22%)
236.51M
SMCISuper Micro Computer Inc
US$ 33.15
(11.62%)
159.61M
VRPXVirpax Pharmaceuticals Inc
US$ 0.5501
(-6.72%)
159.39M
SOUNSoundHound AI Inc
US$ 8.24
(18.05%)
107.91M

AVXL Discussion

Ver más
XenaLives XenaLives 2 horas hace
I agree with the "ton of money" comment...

... I disagree with the rest of your post...

.... IMO it was all about AI manipulation and had nothing to do with fictional "public welfaare".
👍️0
ExtremelyBullishZig ExtremelyBullishZig 2 horas hace
When I come from, AI has replaced all management. When time travel was invented, I was able to escape the AI hell. I am here now to learn about when it gained its legs so I can protect the future.

I cannot devilge what happens to Anavex in the future though, it goes against the FA code of conduct.
👺 1 🤑 1 ❌️ 1
kund kund 3 horas hace
A never-ending catalyst list since 2000.
👎️ 1 👺 1
georgejjl georgejjl 3 horas hace
NEAR TERM NEWS ON THE HORIZON

Alzheimer’s disease: Data from the blarcamesine Phase 2b/3 ANAVEX®2-73-AD-004 trial to be published in an upcoming peer-reviewed journal

Alzheimer’s disease: Full regulatory submission of blarcamesine in Europe (EMA)

Alzheimer’s disease: Analysis of RNA sequencing (RNA-seq) of the Phase 2b/3 data expected 2H 2024

Alzheimer’s disease: Ongoing ATTENTION-AD OLE 96- week trial data expected 2H 2024

Schizophrenia: Top-line data of ANAVEX®3-71 Phase 2 clinical trial

Parkinson’s disease: Initiation of ANAVEX®2-73 imaging-focused trial or Phase 2b/3 >6 months trial

Fragile X: Initiation of ANAVEX®2-73 Phase 2/3 clinical trial

New Rare disease: Initiation of ANAVEX®2-73 Phase 2/3 clinical trial

Publications: Continued clinical publications involving ANAVEX®2-73 and ANAVEX®3-71

Good luck and GOD bless,
👍️0
frrol frrol 3 horas hace
Folks should take note that, regardless of whatever Missling may have claimed about Rett, an upcoming Rett trial is not in the corporate deck. As posted earlier this year, Rett is clearly on the backburner. We have Rett OLEs "ongoing"; the company may be waiting to see what they yield before deciding whether to move forward. But also note that the OLEs are not registered on the clinicaltrials.gov site, and the company has not even mentioned their future readouts in the deck.
👎️ 1 👺 1
mauismart mauismart 4 horas hace
Lots of fud flying here...wow nonstop
👍️ 3
Hoskuld Hoskuld 4 horas hace
It is OK to be wrong sometimes, Mystic, and you are (and apparently were) very wrong on this one. I was wrong when I believed what CM was selling wrt Rett - but that was on me to be that gullible. Just embrace your mistakes old mystic and you will get better at the game.
👺 1 😂 1 ❌️ 1
kund kund 4 horas hace
What promotion? Anavex has CMO, who designed the failed Rett trial, likely did so under the directive of TGD. It's hard to imagine that employees at Anavex have the freedom to provide constructive input on trials or regulatory filings. This seems to be a one-man operation where TGD makes all the decisions and runs the company with an iron fist.
👎️ 1 👺 1
frrol frrol 4 horas hace
It's an administrative task, to be sure. The possible shortcomings causing rejection, however, are not just an easily fixed "you missed a section" but also not having data for a required section. The latter problem can range from the data simply not being in acceptable form (likely fixable) to not having that data (potentially problematic).

(Most applications being accepted is not surprising, and chances of a well-run biotech or pharma not having collected necessary data is low. But this is our first regulatory approval submission, and we did have CRO data issues.)
👺 1
powerwalker powerwalker 4 horas hace
... and your point is? froll told an untruth, twice, knowingly about the filing dates and your response does what to clarify. Go talk to your FUD-buddy about getting his story straight about Anavex's filings.
👍️ 3
oldmystic oldmystic 4 horas hace
Husky,
Clean the cobwebs out ya attic.
Mystic
👍️0
12x 12x 4 horas hace
Under SEC rules, the timing of a company’s 10-K filing depends loosely on its MC at the end of Q2. Companies with an MC above $700M are classified as large accelerated filers and have 60 days to file, for AVXL it's the end of November. For those below $700M, the deadline extends beyond 60 days, into December. From 2021 to 2023, AVXL’s MC as of March 31 exceeded $700M, so its 10-Ks were filed by the end of Nov. However, the filing deadlines, for 2024 and before 2020, fall in December. The company typically files 10-K right after Q4 CC. So the extended filing deadline allows the company to move Q4 CC into Dec.

Here is the filing calendar, you would need to shift the dates as "Anavex has a September 30th fiscal year-end"
https://www.gibsondunn.com/wp-content/uploads/2017/06/SEC-Filing-Deadline-Calendar-2024.pdf

https://www.sec.gov/resources-small-businesses/small-business-compliance-guides/accelerated-filer-large-accelerated-filer-definitions

Year Date 10-K Filed
2023 11/27/23
2022 11/28/22
2021 11/24/21
2020 12/28/20
2019 12/16/19
👍️ 2 🚽 1 ❌️ 1
Hoskuld Hoskuld 4 horas hace
Head of R&D doesn't pull together the eCTD. Regulatory does that work. And the eCTD was largely completed without L-T.
👍️ 2
12x 12x 4 horas hace
Yes, I found that LinkedIn omission interesting. Dr. Lopez-Talavera may be awaiting a promotion following a successful MAA submission, as his previous role as CMO might make the position of Head of R&D appear like a step-down.
👍️ 1
Hoskuld Hoskuld 4 horas hace
Again Hosai, this is clearly not your field of expertise. There is a standard path to approval and Anavex has not done the standard and expected things necessary to guarantee approval. It is counting on a hail mary pass - it is counting on regulatory agencies (starting with the EMA) to make a few exceptions. Probably a better % chance than a hail mary, but had the company simply done the basics that everyone else does then approval would be a certainty in the US and EU.
👍️ 4 👎️ 2 👺 2
Hoskuld Hoskuld 5 horas hace
BakedLangostino, I think your thinking on this is not correct. It is not kind to mismanage a trial so that Rett patients won't have access to an effective treatment. That is what happened. And, no, failing to spend the money was a huge fail.

The old saw you mention - posted in trailers on everyone construction site I have ever been on - doesn't apply here. There is no fast and there is no cheap. There can be good, however. If you go cheap then you ramp up risk - regardless of speed. Speed is limited by the indication and the protocol. Not spending your large cash horde in this case is stupid: the money is there to be spent to build this company. Not spending it means you aren't maximizing the assets. We aren't invested in a money-market fund, but we ARE invested in a biopharma company looking to commercialize sigmar1 agonists.

And the trial was not cheap - we wasted years of patent protection that should have been conserved - worth probably billions of dollars. How many years? 3? 4? For Rett, too - that program is delays 3-4 years, too, now. Very, very expensive.

That you got 10 upvotes for your post blows my mind. You are probably a smart guy in the field you work in, but your take on trials and spending is not a winning one.
👍️ 3 👎️ 2 👺 2
Hosai Hosai 5 horas hace
From what I have have read nearly all apps are "accepted". It's an EMA admin team making sure all parts have been filled in etc. The 'eligility to submit' already passed was a bigger hurdle as that actually involves some CHMP oversight.

However it does seem in general yes that slightly more companies PR on the acceptance rather than the submission.
👍️ 5
frrol frrol 5 horas hace
If the company submits the MAA successfully by 11/25, it will get a 12/27 start, still within 2H 24.

As for announcing submission instead of acceptance/start, you recognize the risk. A credible company would only do that if it either had a very experienced team/TP preparing the MAA or it had already submitted unsuccessfully in a prior cycle(s), fully understood the shortcomings, and is confident it has fully addressed them. So it is possible, but those are big if's.

There are hiccups; recall the CRO delays with our AD data. And there are bigger pitfalls; see our several long missed trial-starts and the troubling AD paper delay. But given the time that's lapsed since we initiated the MAA process, I'm pretty confident we'll get it accepted in this submission cycle or next. (If we don't, it looks less like a hiccup and begins to get troubling.) Let's first see what we hear 11/28-29.
🎯 1 👍️ 5
kund kund 6 horas hace
Dr. Lopez-Talavera appears to be active on LinkedIn but has not updated his profile to reflect any association with Anavex, may be he don't want world to know he works for buffoon CEO. TGD remains at the helm of Anavex, making all the critical decisions. In any other well-functioning company, a CEO would likely have been held accountable and fired following the Rett trial failure.
👍️ 1 👺 1 ❌️ 1
kund kund 6 horas hace
For Anavex to increase its market capitalization, it needs a leadership change. The current buffoon CEO should be replaced with someone who prioritizes execution over filing patents and publishing irrelevant papers like "The New Big Is Small." Buzzword king has no plan other than kick the can. Changing FDA and SEC leadership will not have any impact on Anavex share price.
👍️ 1 👺 2 😏 1 ❌️ 2
bb8675309 bb8675309 7 horas hace
Yes. For the past year or maybe a little less, gas prices have come down from $5.00 plus dollar's a gallon to $3.38 I just paid today. Those continued lower gas prices will help with prices at the store.

As far as Anavex is concerned. I am very bullish on AVXL and believe our MC is way undervalued in the Current CNS space valuation. No way SAVA should be 2x our MC. AVXL should be 2x SAVA / MC IMO. I'm very bullish on the Biotech sector as markets correct and we get new leadership at the SEC and FDA. Corruption needs to be cleaned up. Imo
👍️ 2
powerwalker powerwalker 7 horas hace
I bet $1,000 we don't hear anything official from Anavex on 11/28. If I win on 11/28, then it is $500 there is no news on 11/29 either.

Let's see what we hear on 11/28 or 29.
👍️ 1
georgejjl georgejjl 7 horas hace
I saw gasoline prices today at $2.57 a gallon. The price of gasoline has been decreasing for months. That appears to be deflation.

Although AVXL is trading over $9.00 per share that is the beginning of very good news for AVXL stock.

Good luck and GOD bless,
👍️ 1
boi568 boi568 7 horas hace
There was a ton of money pumped into the system while the economy was shut down and, as intended, it prevented an economic collapse. That was necessary for the public welfare, and it contributed to inflation, as well as pent up demand, some price gouging, and the supply chain disruptions. This stuff is complicated.
🎯 2 👍️ 7
powerwalker powerwalker 7 horas hace
Is there a reason, frroll, you are lying about the timing of the 10-K filing [You do know Anavex has a September 30th fiscal year-end].

The MAA submission is not a FY 2024 event and will not delay the 10K, which has been extended in the last few years.


Year Date 10-K Filed
2023 11/27/23
2022 11/28/22
2021 11/24/21
👍️ 3
ignatiusrielly35 ignatiusrielly35 7 horas hace
LOL
👎️ 1 👺 1
Hoskuld Hoskuld 7 horas hace
I have been both ASM's since December 2022 and it has been CM who has made all the commitments, not your L-T. If you think that L-T and the change in Chairman-ship have changed the company's behavior then you would be wrong.
👍️ 3
bb8675309 bb8675309 8 horas hace
Hi Xena. Yes I agree. AI in general will stream line operations and increase robotics. I know several people who have been laid off from work. I met with my Edward Jones investment guy last week. He said that market valuations are high and we adjusted for that. We are anticipating a big market pull back once Trump gets in office and announces his tariffs. Look for the news media to blame him for the pull back. He did say the he liked the Biotech sector and that Biotech should do better as market corrects.
👍️ 1 👎️ 1 👺 1 😎 2
12x 12x 8 horas hace
Agree. I would also include 11/25 in the list, as I suspect the company will PR the submission to meet the 2H24 milestone and mitigate the risk of any unforeseen issues causing the acceptance date to slip into 2025 if PR only the acceptance. However, if the 11/25 deadline is missed, it is unclear whether the company could still file before 12/31 and claim meeting the 2H24 milestone.
👍️ 1
123tom 123tom 8 horas hace
I'm tempted to sit back and let it run... but that's what I did last time it spiked past 10.... and then it tumbled to 7.20. And I missed a good trade.
If we get some good news for real momentum and volume, then a new support level at 8 can climb to 11,12 and higher, creating a new chart picture. But if we don't get any news coming the next 2 weeks... this 10 area becomes like a trap door waiting to get hammered down. Watching for news and rumors of news, volume, momentum, all the things you're watching for. I'm neutral here. A little nervous about the next jump towards 10 getting slammed down... exactly like last time.
👍️ 1 🤭 1
frrol frrol 8 horas hace
Yes.
👍️ 1
frrol frrol 8 horas hace
The current monthly list, dated 11/7, shows which MAA submissions have been started by the EMA to date. Five were started as of 10/31 (submitted by 10/14). The next 'start date' is 11/28. If we've submitted by 11/11, we will hear on 11/28 or next business day. (If we haven't, we'd have to submit by 11/25 to meet the "2H 2024" company milestone.) The 10-K completion and release is irrelevant for any of this. Let's see what we hear on 11/28 or 29.
👍️ 1 👎️ 2 👺 1
XenaLives XenaLives 9 horas hace
One has to wonder though...

How much of this is AI replacing middle management?
👍️0
poguemahone poguemahone 9 horas hace
Wow!! They took away his title! How about doing something meaningful, such as witholding his bonus, stock options OR even removing him as CEO.

What a joke this company has been.
👍️ 1 👎️ 1 👺 1
12x 12x 10 horas hace
The first column of the EMA link indicates the submission deadline, while the second column shows the corresponding 'start date.' The EMA pre-announces these deadlines and start dates for the year. For applications submitted by each deadline, the EMA typically assigns the start date as the acceptance date. Companies may issue press releases at the time of submission, acceptance, or both, often aligning with the EMA’s pre-announced deadlines or start dates.

When applications encounter issues and cannot be accepted on the corresponding start date, they are often reassigned to the next available start date.

In this case, the November 28 start date applies to applications submitted by the November 11 deadline, while the December 27 start date is for applications submitted by November 25. Missing the November 25 deadline would push the next opportunity to the January 6, 2025 deadline, with a start date of January 23, 2025.

https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation#monthly-lists-2024-64952
👍️ 1 👎️ 1 👺 1
boi568 boi568 10 horas hace
I wouldn't say "acceptance" of the MAA has taken longer than expected (since it has not been announced as submitted), but that preparation, like for the great majority of companies in this position, has taken longer than expected.

It may be that the seven month EMA timeline underestimates what is now being expected of applicants to accomplish by the time of submittal.
👍️ 3
frrol frrol 10 horas hace
Yes. S1 is a highly conserved receptor, and it has been shown pretty conclusively that it has some role in neuronal insult recovery. This paper indirectly supports that. Anavex is trying to show that it has an agonist that can safely induce a therapeutic effect for certain neurodevelopmental and degenerative conditions. The preclinical and clinical data on this is directly supportive.
👍️ 4
Hosai Hosai 10 horas hace
In pointing out the disruption to SR1 pathway (as seen in Sertraline inverse agonism) leading to negative outcomes in learning and plasticity and especially so in the hippocampus, it would seemingly indirectly support the treatment potential of a SR1 agonist.
Obv this is Nature too so a very respected journal.
👍️ 2
12x 12x 10 horas hace
The BOD has taken several actions since the 2022 CTAD fallout. Removing CM's Chair title is one significant step, along with hiring and promoting senior management. A key move was bringing on Dr. Lopez-Talavera as head of R&D. Notably, he has been featured in every company PR since his hiring, making milestone commitment statements instead of CM. This signals that Dr. Lopez-Talavera is now tasked with leading the team to deliver on these commitments. A review of his LinkedIn profile will provide a few surprises...
👍️ 6 👎️ 2 👺 1
Hosai Hosai 10 horas hace
Where does it say 25th Nov is final submission deadline?

From what I've seen companies often submit about 2-3 weeks before their application is "accepted". They tend to PR the acceptance on the same day as ends up being their start date or a few days after the start date. There is a new start date per month and usually 6-7 companies share that start date.

Going by prior years it looks like the last 2 start dates for this year would be around Nov 28th and Dec 27th so assuming they have already submitted it would mean an acceptence PR on Fri 29th or Mon 2nd or if not would be late Dec/early Jan for acceptance PR (though they could PR that they have submitted if if they submit in Dec as some PR when they submit rather than upon acceptance).
👍️ 3
Hosai Hosai 10 horas hace
I did say "indirectly" as SSRIs is primary focus of paper however in parts it seems to link S1R with brain health and in particular the hippocampus as-well as in general protecting brain cells.
I'm not sure the degree to which this was already know however.
👍️ 1
12x 12x 10 horas hace
Since Blarcamesine is absent from the most recent (November) EMA monthly list of drug applications under consideration, it is reasonable to conclude that the MAA has not yet been filed as of November 6. Notably, companies often align their submissions with EMA deadlines, as evidenced by the correlation between previously announced submission dates and these deadlines. With November 25 being the final MAA submission deadline for 2024, it is logical to assume this is the target date for submission. Historically, MAA submissions are typically accepted within three weeks. Therefore, timely submission is critical. This timing also appears to correlate with the delay in the company's Q4 CC.

https://www.ema.europa.eu/en/medicines/medicines-human-use-under-evaluation#monthly-lists-2024-64952
👎️ 1 👺 1
kund kund 11 horas hace
Nothing will be achieved this year—it's the same story, year after year. This CEO is hot air, slogans and buzzwords. He can't execute, extremely incompetent management team.
👍️ 2 👎️ 2 👺 2 ☹️ 1
Bourbon_on_my_cornflakes Bourbon_on_my_cornflakes 11 horas hace
With 18 workdays left in the year, it seems unlikely that any of the H2 deliverables will be met, aside from the confirmed MAA filing (per Dr. Lopez-Talavera in the PR)

No surprise there from the glacial AVXL mgt team, who fails to meet their own milestones more regularly than a Swiss watch.

The real surprise would be if Lopez -Talavera is right and the MMA actually gets filed.

That is the only milestone that matters, but we would be lucky if it is filed Feb'ish.
👍️ 2 👎️ 1 👺 1
powerwalker powerwalker 11 horas hace
This will be a critical test for the new management team

This is NOT a new management team. It is a management team that has some new members: Jin and Goldberger have been around for two years, either as EE or contractor, so I would not call them new. This is Dr. Missling's management team as it has been for 11+ years, regardless of whom comprises it.
👍️ 3
frrol frrol 11 horas hace
The MAA submission is not a FY 2024 event and will not delay the 10K, which has been extended in the last few years. We'll hear about the MAA when it's successfully submitted and accepted by the EMA.

Acceptance has taken somewhat longer than the company expected, as we are over the 7 month minimum. Hopefully it is not a matter of critical data availability. We should hear one way or the other soon.
👎️ 1 👺 1
frrol frrol 11 horas hace
The paper is on SSRIs, and singles out sertraline, examining how it might differ from other SSRI's in that it has a negative side-effect on neuro-inflammation and plasticity (partly because it seems to be an S1 inverse agonist, suppressing its action).
👎️ 1 👺 1
BIOChecker4 BIOChecker4 12 horas hace
Two words: good luck.
👍️0
12x 12x 12 horas hace
Many speculate that this year's Q4 CC may be delayed until December to accommodate the MAA submission. The Q2 market cap dip below $700M (falling under the large accelerated filer threshold) provided a rare opportunity to extend the 10-K filing deadline to December. With 18 workdays left in the year, it seems unlikely that any of the H2 deliverables will be met, aside from the confirmed MAA filing (per Dr. Lopez-Talavera in the PR) and potentially the interim OLE results. This will be a critical test for the new management team—Lopez-Talavera, Jin, Kellmeyer, Edwards, and Goldberger—to demonstrate their ability to deliver on milestones, starting Monday - MAA deadline date Nov 25...
👍️ 10
bb8675309 bb8675309 14 horas hace
Interesting read: Companies that announced Major Layoffs and Hiring Freezes

real state of current economy. Market is being propped up by 7 companies. Buffet and Bezos holding record amount of cash.

https://www.afr.com/wealth/investing/buffett-s-499b-cash-hoard-is-an-early-warning-signal-20241122-p5ksvo

https://intellizence.com/insights/layoff-downsizing/major-companies-that-announced-mass-layoffs/
👍️ 2 👎️ 1 👺 1

Su Consulta Reciente

NASDAQ
AVXL
Anavex Life Sciences
POLO
LINKBTC
ChainLink Token
BITMOT
961324
Eib Tf 3% Nv29 Pln
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados